Evidence Based Hair

Season 3, Episode 7 (Scalp Biopsies, Chronic Hives from Laser Hair Removal, Hair Pigmentation from Nilotinib, Sebderm & Osteoporosis, Finasteride and Bladder Ca)

A mix of recently published studies in hair loss
 
IRON PILL GASTRITIS
 
Koch R et al (starts at5 5:19). Case report: Rapid onset, ischemic-type gastritis after initiating oral iron supplementation. Front Med (Lausanne) 2022 Nov 3;9:1010897.
 
Laine LA et al. (starts at 9:17). Effect of oral iron therapy on the upper gastrointestinal tract. A prospective evaluation. Dig Dis Sci. (1988) 33:172–7. doi: 10.1007/BF01535729
 
 
 
COMPARISON OF HORIZONTAL VS VERTICAL SECTIONING FOR SCALP BIOPSIES
 
Yadav et al (starts at 14:05). Vertical versus transverse sectioning in histopathological diagnosis of alopecia: A comparative study. Indian J Dermatol Venereol Leprol. 2022 Sep 17;1-4.
 
 
Du et al (starts at 22:40). Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis. Eur J Dermatol . 2016 Aug 1;26(4):361-9. doi: 10.1684/ejd.2016.2797.
 
 
Nguyen J et al (starts at 27:13). The HoVert technique: A novel method for the sectioning of alopecia biopsies. J Cutan Pathol. 2011;38:401–6.
 
 
PERSISTENT HIVES AFTER LASER HAIR REMOVAL
 
Dorgham N et al (starts at 27:36). Severe persistent urticaria following laser hair reduction. J Cosmet Dermatol. 2022 Sep 15.
 
Landa N et al (starts at . Urticaria induced by laser epilation: a clinical and histopathological study with extended follow-up in 36 patients. Lasers Surg Med. 2012;44(5):384-389.
 
 
 
HAIR REPIGMENTATION FROM NILOTINIB
Kockerols CCB, Westerweel PE (starts at 34:24). Hair Repigmentation Induced by Nilotinib. N Engl J Med. 2022 Aug 11;387(6):e12. doi: 10.1056/NEJMicm2119953. Epub 2022 Aug 6.
 
 
SEBORRHEIC DERMATITIS AND OSTEOPOROSIS
Ying-Yi Lu et al (starts at 37:01) . Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
 
 
SEBORRHEIC DERMATITIS AND PARKINSON’S DISEASE
 
Tomic S et al (starts at 47:09). Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson's Disease. J Clin Neurol. 2022 Nov;18(6):628-634.
 
FINASTERIDE AND BLADDER CANCER.
 
Garg H et al (starts at 53:52). Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis. Clin Genitourin Cancer. 2022 Oct 29;S1558-7673(22)00221-X

Season 3, Episode 6 (Hydroxychloroquine and Oral Minoxidil for LPP, Gout in AKN, Shingles and EPDS, Renbok phenomenon, ACD in FFA/LPP)

LEARNING OBJECTIVES
By the end of the podcast, the listener should be able to
Discuss the benefits of HCQ in LPP
Outline allergens that may be relevant in LPP/FFA
Discuss the benefits of LDOM in LPP
Describe the Renbok phenomenon and how it relates to FFA
Outline the potential triggers for EPDS
Describe the relationship between AKN and gout
 
 
EFFICACY OF HYDROXYCHLOROQUINE IN LICHEN PLANOPILARIS
 
Vastarella M et al (starts at 6:08). Efficacy and safety of hydroxychloroquine for the management of lichen planopilaris in a real-life setting. Ital J Dermatol Venerol. 2022 Jun;157(3):296-297.
 
Chiang C et al (starts at 14:17). Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010 Mar;62(3):387-92.
 
Dhonncha EN et al (starts at 16:05). The role of hydroxychloroquine in the treatment of lichen planopilaris: A retrospective case series and review. Dermatol Ther. 2017 May;30(3).
 
 
 
ALLERGIC CONTACT DERMATITIS IN LICHEN PLANOPILARIS AND FRONTAL FIBROSING ALOPECIA
 
Prasad et al (starts at 18:38). Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: A cohort study J Am Acad Dermatol Aug 2020
 
Shtaynberger B et al (starts at 22:51). The Prevalence of Type IV Hypersensitivity in Patients With Lichen Planopilaris and Frontal Fibrosing Alopecia. Dermatitis. 2022 Oct 17.
 
 
 
USE OF ORAL MINOXIDIL IN LICHEN PLANOPILARIS
 
Vano-Galvan S et al (starts at 36:42). Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol 2021 Jun;84(6):1684-1686.
 
 
Giuseppe Gallo et al (starts at 37:45). Low-dose oral minoxidil in female patients with lichen planopilaris: Real-life experience. J Eur Acad Dermatol Venereol. 2022 Aug 16
 
 
 
 
RENBOK PHENOMENON IN FRONTAL FIBROSING ALOPECIA
 
Sławińska M et al (starts at 42:29). Frontal fibrosing alopecia sparing a dermal melanocytic nevus: a report of two cases of Renbök phenomenon. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):e1042-e1043.
 
EROSIVE PUSTULAR DERMATOSIS AND SHINGLES
 
Salah NB et al (starts at 45:21). Erosive pustular dermatosis of the scalp in the COVID-19 era. J Cosmet Dermatol. 2022 Nov 14.
 
Akpandak I et al (starts at 50:55). Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine. JAMA Netw Open 2022 Nov 1;5(11):e2242240.
 
 
RISK OF GOUT IN ACNE KELOIDALIS
Eran Shavit et al (starts at 53:40). The burden of gout in acne keloidalis nuchae-Insights from a population-based study. J Cosmet Dermatol. 2022 Nov 8.

Season 3, Episode 5 (TE in Children, Post COVID Hair Loss, NAC for TTM and Trichobezoar)

Season 3, Episode 5

Season 3, Episode 4 (Oral Minoxidil for AGA, JAKI for AGA, PRP for AGA,COVID Vaccines and AA Risk, AA Rising Prevalence)

Studies in Androgenetic Alopecia and Alopecia Areata
 
STUDIES REFERENCED
 
MINOXIDIL CONCENTRATIONS
 
Singh et al (starts at 10:10). Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? Clin Exp Dermatol. 2022 Nov;47(11):1951-1955
 
Olsen EA, Dunlap FE, Funicella T et al (starts at 13:22). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377–85
 
McCoy J, Goren A, Kovacevic M, Shapiro J (starts at 16:02). Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 2016;30: 1153–5
 
Goldust M (starts at 17:25). Minoxidil 15% solution versus minoxidil 5%solution in the treatment of androgenetic alopecia. Br JDermatol 2020;183(Suppl): 91 (abstract BH107)
 
Ghonemy S, Alarawi A, Bessar H (starts at 18:11). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgeneticalopecia: a trichoscopic evaluation. J Dermatolog Treat 2021;32: 236–41
 
 
JAK INHBITORS FOR ANDROGENETIC ALOPECIA
 
Casale F et al (starts at 22:19). Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia? Int J Dermatol. 2022 Nov;61(11):e457-e458.
 
BOTOX FOR ANDROGENETIC ALOPECIA
 
English RS Jr and Ruiz S (starts at 29:30). Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review. Skin Appendage Disord. 2022 Mar;8(2):93-100
 
Shon U, Kim MH, Lee DY, Kim SH, Park BC (starts at 33:48). The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020 Dec;83(6):1838–9.
 
 
PLATELET RICH PLASMA TREATMENTS FOR ANDROGENETIC ALOPECIA
Gupta AK and Bamimore M (starts at 39:09). Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
 
de Oliveira AFQ et al (starts at 42:25). Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. J Dermatolog Treat. 2022 Oct 31:1-11.
 
LOW DOSE ORAL MINOXIDIL SIDE EFFECTS  
Dlova et al (starts 45:41). Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022 Aug 11;28:94-96.
 
Randolph M, Tosti A (starts at 53:22). Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3): 737-746.
 
 
LOW DOSE ORAL MINOXIDIL EFFICACY AND SAFETY  
 
Gupta AK et al (starts at 57:33). There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
 
 
JAK INHIBITORS AND VENOUS THROMBOEMBOLISM
Chen T-L et al (starts at 1:02:14). Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Aug 24;e223516.
 
King B et al (1:05:33). Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
 
Misra D et al (starts at 1:11:19). Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box. Clin Rheumatol. 2022 Oct 20.
 
 
RISING PREVALENCE OF ALOPECIA AREATA IN JAPAN
 
Campos-Alberto E et al (starts at 1:13:00). Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database. J Dermatol. 2022 Nov 2.
 
COVID VACCINATION AND ALOPECIA AREATA RISK
 
Tassone F et al (starts at 1:15:21). Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study. Vaccines (Basel). 2022 Sep 5;10(9):1467.
 
Nguyen B and Tosti A (starts at 1:21:22). Alopecia areata after COVID-19. J Eur Acad Dermatol Venereol. 2022 Aug 11;10.1111/jdv.18491.
 
Babadjouni  A et al (starts at 1:30:21). COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy. JAAD Case Rep . 2022 Nov;29:181-185.
 
Chen C-H et al (starts at 1:36:55). Intractable alopecia areata following the second dose of COVID-19 vaccination: Report of two cases. Dermatol Ther. 2022 Sep;35(9):e15689.
 

Season 3, Episode 3 (Resilience in AA, Hair Repigmentation and Melanoma, Accuracy of TikTok, Hair Straighteners & Uterine Cancer, Sebaceous Gland Atrophy in Seborrheic Dermatitis)

Recording of the Evidence Based Hair Podcast for the Oct 24, 2022 issue. 
 
STUDIES REFERENCED
Han JJ et al (starts at 5:28) Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study. J Am Acad Dermatol. 2022 Jul;87(1):151-153.
 
Gressler J et al (starts at 20:55 ). Re-pigmentation of scalp hair - A feature of early melanoma. Am J Med. 2022 Sep 25;S0002-9343(22)00711-2.
 
Lackey A et al (starts at 24:09) Repigmentation of gray hairs with lentigo maligna and response to topical imiquimod. JAAD Case Rep. 2019 Dec; 5(12): 1015–1017
 
Nguyen et al (starts at 27:18). Characterizing and assessing the reliability of TikTok's most viewed alopecia-related videos. J Eur Acad Dermatol Venereol. 2022 Aug 14.
 
Nagrani NS, Goldberg LJ (starts at 37:24). Sebaceous gland atrophy in seborrheic dermatitis of the scalp; a pilot study. J Cutan Pathol. 2022 Nov;49(11):988-992.
 
Headington JT, Gupta AK, Goldfarb MT, et al (starts at 41:26). A morphometric and histologic study of the scalp in psoriasis. Paradoxical sebaceous gland atrophy and decreased hair shaft diameters without alopecia. Arch Dermatol. 1989;125:639-642.
 
Klein EJ et al (starts at 46:38). Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. JAAD Int. 2022 Aug 30;9:69-71.
 
Chang CJ et al (starts at 59:21). Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.

Season 3, Episode 2 (LPP, FFA, Checkpoint Inhibitor induced LPP, Scarring Alopecia ”Gene Signatures”, Alopecic and Aseptic Nodules of the Scalp)

Recording of the Evidence Based Hair Podcast for the Oct 17, 2022 issue. 
 
LICHEN PLANOPILARIS COMORBIDITY STUDIES
Conic et al (starts 8:19). Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.
Joshi et al (starts 9:59). Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
Nasimi et al (starts 15:45) Comorbidities in Patients with Lichen Planopilaris: A Case-Control Study. Skin Appendage Disord. 2022 Jul;8(4):302-306.
 
FRONTAL FIBROSING ALOPECIA STUDIES
Imhof RL et al (starts 20:21). Eyebrow hair loss as a prognostic factor for frontal fibrosing alopecia. JAAD Int. 2022 Aug 18;
Rosales Santillan M et al (starts 26:52). Exploring potential decreasing age of patients with frontal fibrosing alopecia. JAAD Int. 2022 Jul 22;
Doche et al (starts 35:52). "Normal-appearing" scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients. Exp Dermatol . 2020 Mar;29(3):278-281.
Porrino-Bustamante et al (starts 36:30). Frontal Fibrosing Alopecia: A Histopathological Comparison of the Frontal Hairline with Normal-Appearing Scalp. J Clin Med 2022; Jul 15;11(14):4121
 
CHECKPOINT INHIBITORS AND SCARRING ALOPECIA
Braasch et al (starts 45:25). Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases. Acta Derm Venereol. 2022 Oct 11;102:adv00792.
 
GENE SIGNATURES IN PRIMARY SCARRING ALOPECIA
Wang EHC et al (starts 55:10). Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways. PNAS Nexus . 2022 Jul 11;1(3):pgac111
 
ALOPECIC AND ASEPTIC NODULES OF THE SCALP (AANS):
Luu NHC et al (starts 1:06:42). Alopecic and Aseptic Nodules of the Scalp: A New Entity or a Minor Form of Dissecting Cellulitis? Int J Trichology. 2022 Jul-Aug;14(4):120-124

Season 3, Episode 1 (Isotretinoin, Trichotillomania, Blue Sclera, Omicron, Tinea Capitis from Guinea Pigs)

Recording of the Evidence Based Hair Podcast for the Oct 11, 2022 issue. 
TINEA CAPITIS STUDIES
Cukierman E et al (starts at 5:18). Alopecia and pet: a case report. Einstein (Sao Paulo). 2022 Jul 4;20:eRC6881.
 
TELOGEN EFFLUVIUM - COVID 19
Visconti A et al (starts at 20:00) Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App. Br J Dermatol. 2022 Jul 22;
 
TELOGEN EFFLUVIUM - ISOTRETINOIN
Tran PT et al (starts at 29:30) Characteristics of Patients with Hair Loss after Isotretinoin Treatment: A Retrospective Review Study. Int J Trichology. 2022 Jul-Aug;14(4):125-127.
 
TRICHOTILLOMANIA STUDIES
Grant JE and Chamberlain SR (starts at 42:17). Natural recovery in trichotillomania. Aust N Z J Psychiatry. 2022 Oct;56(10):1357-1362
 
Chesivoir EK et al (starts at 47:30). Comorbid trichotillomania and attention deficit hyperactivity disorder in adults. Psychiatry. 2022 Jul; TELOGEN EFFLUVIUM -
 
IRON DEFICIENCY
 
Kano Y. Blue sclera (starts at 55:33): An overlooked finding of iron deficiency. Cleve Clin J Med. 2022 Oct 3;89(10):549-550.
 
 

Season 2, Episode 10 (Oral minoxidil, Hair Fibers, HCQ in Pregnancy, Teriflunomide-induced Hair Loss, Do it Yourself Haircare, Premature Greying of Hair)

ORAL MINOXIDIL IN PEDIATRICS
 
Jerjen R et al (starts at 12:33). Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184(5):977-978.
Nicolas-Ruanes et al (starts at 15:33). Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol. 2022 Apr 26;
John JM et al (starts at 17:24). Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review. J Am Acad Dermatol . 2022 Jul 5;S0190-9622(22)02245-9.
 
HAIR FIBERS AND CAMOUFLAGE
Ring and Keller (starts at 25:13). Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients. J Am Acad Dermatol. 2017 Jun;76(6):1186-1189
Babadjouni A et al (starts at 28:15). Patient Satisfaction and Adverse Effects Following the use of Topical Hair Fiber Fillers. Int J Trichology. 2022 May-Jun; 14(3): 97–102
 
HYDROXYCHLOROQUINE IN PREGNANCY
Reynolds JA et al (starts at 34:38). Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford). 2022 Jun 29:
Sperber K et al (starts at 38:25). Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9.
Kaplan Y et al (starts at 39:17). Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 May;81(5):835-48.
Clowse MEB et al (starts at 40:27). Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022 Mar;9(1):e000651.
Huybrechts K et al (starts at 42:37). Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021 Mar;224(3):290.e1-290.e22
Huybrechts K et al (starts at 45:20). Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence. Am J Obstet Gynecol. 2021 May;224(5):549-550.
Bérard et al (starts at 46:58). Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Front Pharmacol. 2021 Aug 2;12:722511.
Howley et al (starts at 47:17). Maternal exposure to hydroxychloroquine and birth defects. Birth Defects Res. 2021 Oct 15;113(17):1245-1256.
Andersson et al (starts at 47:34). Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021 May 14;60(5):2317-2326.
 
TERIFLUNOMIDE INDUCED HAIR LOSS IN MULTIPLE SCLEROSIS
Travis LH et al (starts at 53:28). Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice? Neurol Ther. 2018 Dec; 7(2): 341–347.
Porwal MH et al (starts at 55:41). Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies. J Cent Nerv Syst Dis. 2022 Jun 23;14:11795735221109674.
 
DO IT YOURSELF LOW-ALLERGEN PRODUCTS
Xiong M and Warshaw EM. (starts at 1:05:45) Hair Care Product Hacks: Do It Yourself Alternatives. Dermatitis. 2022 Jun 29.
Zirwas M and Moennich J (starts at 1:00:25). Shampoos. Dermatitis. 2009 Mar-Apr;20(2):106-10
Tawfik M, Rodriguez-Homs LG, Alexander T, et al (starts at 1:01:10). Allergen content of  best-selling ethnic versus nonethnic shampoos, conditioners, and styling products. Dermatitis 2021;32(2):101–110
https://donovanmedical.com/diy
 
PREMATURE GREYING (EARLY CANITIES)
Anggraini et al (starts at 1:08:50). Risk Factors Associated with Premature Hair Greying of Young Adult. Open Access Maced J Med Sci . 2019 Nov 14;7(22):3762-3764.
Dawber RP (starts at 1:09:12). Integumentary associations of pernicious anaemia. Br J Dermatol . 1970 Mar;82(3):221-3.
Mosley JG and Gibbs AC (starts at 1:09:50). Premature grey hair and hair loss among smokers: a new opportunity for health education? British Medical Journal 1996; 313: 1616.
Bhat RM et al (starts at 1:10:21). Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. Int J Trichology. 2013;5:17–21.
Chang H-C and Sung C-W (starts at 1:10:35). Association between serum levels of minerals and premature hair graying: a systematic review and meta-analysis. Int J Dermatol. 2020 Oct;59(10):e378-e380.
Schnohr P et al (starts at 1:12:35). Longevity and gray hair, baldness, facial wrinkles, and arcus senilis in 13,000 men and women: The Copenhagen city heart study. J Gerontol A Biol Sci Med Sci. 1998;53:M347–50.
Schnohr P et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J  1995 Nov;130(5):1003-10.
 
Kocaman SA et al (starts at 1:14:10) . The degree of premature hair graying as an independent risk marker for coronary artery disease: A predictor of biological age rather than chronological age. Anadolu Kardiyol Derg 2012;12:457-63. 
Paik S et al (starts at 1:14:25). Association Between Premature Hair Greying and Metabolic Risk Factors: A Cross-sectional Study. Acta Derm Venereo. 2018 Aug 29;98(8):748-752.
Mahendiratta S et al (starts at 1:15:09). Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal-A systematic review and meta-analysis. Dermatol Ther. 2020 Nov;33(6):e13990.
Das S et al (starts at 1:15:51) Cardiovascular risk markers in premature canities. Indian J Dermatol Venereol Leprol. 2022 Jun 30;1-5.

Season 2, Episode 9 (Isotretinoin and Finasteride for FFA, Eyelash Loss in FFA, Male FFA, LPP Incidence and Prevalence, CCCA Quality of Life)

FRONTAL FIBROSING ALOPECIA :
ISOTRETINOIN VS FINASTERIDE
Rakowska A, et al (starts at 9:15). Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases. J Drugs Dermatol. 2017.
Rokni GR et al (starts at 10:43). Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia - A randomized controlled trial. J Cosmet Dermatol. 2022 Jul 11.
 
FRONTAL FIBROSING ALOPECIA : EYELASH INVOLVEMENT
Salas-Callo C et al (starts at 16:14). Eyelash involvement in frontal fibrosing alopecia: A prospective study. J Am Acad Dermatol 2022 Jul;87(1):232-234.
 
FRONTAL FIBROSING ALOPECIA : QUALITY OF LIFE
David Saceda-Corralo et al (starts at 22:52). Health-Related Quality of Life in Patients With Frontal Fibrosing Alopecia. JAMA Dermatol. 2018 Apr 1;154(4):479-480.
Varghae A et al (starts at 24:43). Assessment of health-related quality of life in patients with frontal fibrosing alopecia. J Cosmet Dermatol. 2022 Jun 27.
 
FRONTAL FIBROSING ALOPECIA : MALE FFA STUDIES OF ORAL MINOXIDIL AND FINASTERIDE/DUTASTERIDE
Moussa A et al (starts at 30:00). Clinical features and treatment outcomes of frontal fibrosing alopecia in men. Int J Dermatol. 2022 Jun 21
LPP PREVALENCE STUDIES
Trager MH et al (starts at 40:50). Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169
Lavian J et al (starts at 41:37). Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system.Dermatol Online J. 2021 Aug 15;27(8).
Lim S H et al (starts at 42:29). Rapidly increasing incidence and prevalence of lichen planopilaris in an Asian population: A Korean nationwide population-based study. J Dermatol. 2022 Jun 21.
Joshi TP et al (starts at 49:10). Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70
 
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA: QUALITY OF LIFE
Akintilo et al (starts at 54:48). Health care barriers and quality of life in central centrifugal cicatricial alopecia patients. Cutis. 2018 Dec;102(6):427-432.
 
Maranga et al (starts at 56:49). Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study. Br J Dermatol. 2022 Jun 15.
 
 
CONCLUSION AND SUMMARY - starts at 58:46

Season 2, Episode 8 (COVID shedding, Trichotillomania, Traction Alopecia, Tinea Capitis Carrier State)

STUDIES REFERENCED
 
COVID RELATED SHEDDING
 
Mazeto IFS et al (starts at 6:09). Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
 
Czech T et al (starts at 14:30). Characteristics of Hair Loss after COVID-19: Systematic Scoping Review. J Cosmet Dermatol. 2022 Jul 8.
 
 
TRICTHOTILLOMANIA
 
Thomson H et al (starts at 24:58). Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. J Psychiatr Res. 2022 Jul 1;153:73-81.
 
TINEA CAPITIS  
 
Lecerf P et al (starts at 30:10). Asymptomatic Scalp Carriage among Household Contacts of Children Affected by Tinea Capitis: A Prospective Study in the Metropolitan Area of Brussels, Belgium.  Skin Appendage Disord. 2022 May;8(3):200-205.
 
TRACTION ALOPECIA
 
Lucia GS et al (starts at 42:30). Traction alopecia: Neglected in women and children of color. J Am Acad Dermatol. 2022 May 28;
 
FINAL COMMENTS AND SUMMARY - starts at 49:03